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Pathophysiology of Heart Failure
Mihai Gheorghiade, MD,* and Jeffrey B. Lakier, MD*

Heart failure occurs when the heart is unable to maintain a cardiac output sufficient to satisfy the
oxygen requirements of the body despite adequate blood volume and hemoglobin content. Regardless
ofthe initial cause of heart failure and in spite of compensatory mechanisms, patients often follow a
course of worsening heart failure that is characterized by a low cardiac output, high filling pressures,
and increased peripheral vascular resistance. In addition to persistence of the initiating event,
cardiac deterioration may be caused or aggravated by a variety of factors including depletion
of cardiac norepinephrine stores, down-regulation of myocardial beta-adrenergic receptors,
microvascular spasm with resultant further cellular necrosis, and subendocardial ischemia
perpetuating myocardial failure. (Henry Ford Hosp MedJ 1986:34:153-5)

H

eart failure occurs when the heart is unable to maintain a
cardiac output sufficient to satisfy the oxygen requirements
of the body despite adequate blood volume and hemoglobin content ( I ) . Myocardial failure, heart failure without myocardial
failure (eg, tricuspid stenosis and constrictive pericarditis which
interfere with cardiac filling, or rhythm disturbances), and circulatory volume overload resulting from abnormal salt and
water retention without a disturbance of cardiac function per se
(2) all may result in the clinical syndrome of heart failure. This
review focuses on the pathophysiology of heart muscle dysfunction that causes myocardial failure.

Myocardial Failure
Three different mechanisms may be responsible for myocardial failure (3): 1) primary myocardial failure (cardiomyopathy)
in which cardiac contractility is severely compromised secondary to either a quantitative loss of myocardial cells due to
destmction or replacement and/or a qualitative defect in myocardial cells; 2) failure due to pressure overload (ie, in aortic stenosis) in which the principal cause of the reduced stroke volume
is obstmction to ventricular ejection; and 3) failure due to volume overload in which a significant portion of the total ejected
cardiac output fails to reach the peripheral tissues due to regurgitation into the atrium (mitral regurgitation) or into the ventricle (aortic regurgitation) (Figure),
Despite considerable effort directed toward clarifying the
fundamental processes involved in myocardial contractile deterioration, a distinct biochemical defect responsible for heart
failure has not been identified (4).
Myocardial failure, which frequently develops gradually, is
preceded by a phase in which the whole heart, or the remaining
viable portion, hypertrophies and dilates (5). This permits compensation for the loss of myocardial cells or hemodynamic overload. Why the initial compensatory hypertrophy and dilatation
progress to myocardial failure is unknown (6). Available data
suggest that the alteration in the function of myocardial cells and
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not their increased size is responsible for this course of events
(5). Chronic ischemia (7,8), mitochondrial dysfunction (9), depletion of myocardial energy supplies (10), defective myocardial
energy utilization (11), and abnormalities in excitation-contraction coupling (12) are all possible mechanisms. Recent interest
has focused on the role of abnormalities in calcium transport in
heart failure (13), Theoretically, defective calcium transport
could intenupt maximal excitation-contraction coupling by several mechanisms: decreased calcium availability to the sarcolemma, decreased calcium transport across this membrane,
altered calcium release or uptake by the intracellular sarcoplasmic reticulum, or decreased calcium removal from the contractile protein.
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Figure—Pathophysiology of heart failure. *Persistence of a primary etiology for the initial event (eg, alcohol, aortic stenosis,
persistent ischemia) will result in further
deterioration.
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Compensatory Mechanisms
Regardless of the etiology of heart failure, several circulatory
adjustments tend to compensate for the fall in cardiac output.
The initial adjustment to a decrease in contractility or volume
overioad is cardiac dilatation. As the preload increases, a limited
increase occurs in sarcomere length, and additional sarcomeres
are recmited to augment ventricular function. This represents
the Frank-Stariing mechanism (14), However, this mechanism
may not operate in patients with severely dilated ventricles when
further ventricular dilatation may cause secondary mitral or tricuspid insufficiency (15,16) and increase in wall tension which
may further reduce stroke volume (17). In addition, subendocardial ischemia may supervene (18).
A second compensatory mechanism is fluid retention. Plasma
volume is increased due to reabsorption of salt and water by the
kidneys (3), The origins of the sodium retention include elevations in renal venous pressure, redistribution of the diminished
renal blood flow toward the juxtamedullary nephron, activation
of the renin-angiotensin-aldosterone system (19), and lack ofthe
natriuretic substance. In chronic heart failure, antidiuretic hormone titers are high despite augmented stretch of left atrial
receptors which normally inhibit the release of this hormone
(20-22),
Circulating catecholamines (23) which augment myocardial
contractility and blood pressure comprise a third mechanism.
Finally, myocardial hypertrophy (24) may occur, providing a
fundamental compensatory mechanism when an excessive pressure or volume load is imposed on the heart.
Regardless of the initial cause of heart failure and despite
compensatory mechanisms, patients often follow a course of
worsening heart failure that is characterized by a low cardiac
output, high filling pressures, and increased peripheral vascular
resistance (25),

Possible Causes for Further
Myocardial Deterioration
In addition to persistence or progression of the initiating
event, cardiac deterioration may be caused or aggravated by a
variety of factors including depletion of cardiac norepinephrine
stores, down-regulation of myocardial beta-adrenergic receptors, microvascular spasm with resultant further cellular necrosis, and subendocardial ischemia perpetuating myocardial
failure (Figure),
Depletion of cardiac norepinephrine stores
The role of catecholamines in heart failure is discussed in
detail by Goldstein in this issue of the Journal (26). Control
subjects have a modest adrenergic tone, low levels of plasma
catecholamines, and a significant store of myocardial norepinephrine (25). With mild degrees of heart failure, plasma
catecholamine levels rise only moderately, and myocardial norepinephrine supplies are not depleted (25). With chronic severe
heart failure, plasma catecholamines are increased markedly
and myocardial norepinephrine stores are diminished (27).
Experimentally, after the production of heart failure in dogs
(28), ventricular norepinephrine concentration falls markedly
and the infusion of norepinephrine does not raise cardiac nor-
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epinephrine stores. The reduced capacity to retain administered
norepinephrine is probably due to a reduction in the total number of neurones in the heart (1). This may be responsible for loss
of the adrenergic support which could intensify the severity of
the heart failure.
Down-regulation of beta-receptors
Compensatory adrenergic stimulation in patients with heart
failure occurs for a limited period (29). In chronic heart failure
the activity of endogenous catecholamines is rapidly terminated
through uptake into intraneuronal and extraneuronal sites where
metabolic degradation occurs (29). Brief exposure to adrenergic
agonists transforms the active form of the beta-adrenergic receptor to a low-affinity form that interferes with production of adenylate cyclase (30). Prolonged exposure to adrenergic agonists
results in a significant decrease in beta-receptor density in
the cell membrane. This phenomenon is called receptor downregulation (29). Because of a decrease in beta-receptor density,
circulating catecholamines no longer stimulate the failing heart
to the same degree, and myocardial failure progresses (30,31).
The high levels of catecholamine observed in patients with severe heart failure (32) in the presence of decreased beta-receptors on cell membranes of smooth muscle may actually reduce
cardiac output by increasing peripheral resistance through unopposed alpha-adrenergic stimulation. Available data suggest that
there could be a group of patients with heart failure in whom
long-term beta-adrenergic blockade will improve myocardial
function and prolong life (33,34). The benefit that has been
observed from beta-blocker therapy may be the result of up-regulation of beta-adrenergic receptors, allowing restoration of
catecholamine responsiveness which results in improved myocardial function.
Microvascular spasm
Dilated cardiomyopathy may possibly begin with focal transient microvascular spasm that causes myocyte necrosis and,
subsequently,fibrosis(35), Factor et al (36) showed that the Syrian hamster develops focal myocardial necrosis beginning at one
month of age, which leads to eventual ventricular failure within
one year. Those authors demonstrated that transient spasm of
small blood vessels, probably secondary to vasoactive substances, may cause myocytolytic necrosis. According to Sonnenblick et al (35), verapamil, a channel calcium antagonist,
prevents the focal necrosis and fibrosis in the Syrian hamster
myocardium. The similarity of this disease to human and experimental cardiomyopathy suggests that microvascular spasm may
be a common denominator in many different cardiomyopathic
syndromes. The perfusion defects (37) seen on thallium-201
scans of patients with idiopathic dilated cardiomyopathy may
represent areas of myocardial fibrosis and scaning resulting
from microvasospasm.
Subendocardial ischemia
Studies (38,39) suggest that in patients with a dilated cardiomyopathy the subendocardial muscle first loses its ATP, followed by vacuolization and finally fibrosis. This progressive
deterioration can be due partly to insufficient coronary blood
flow to the subendocardium, which initiates a vicious cycle
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that worsens the heart failure and further decreases coronary
blood flow (18), This hypothesis has some implications in the
therapeutics of heart failure. Decreasing ventricular size, lowering left ventricular end-diastolic pressure, or decreasing heart
rate may improve subendocardial perfusion and conect the
imbalance of energy supply and demand (39), Benefits of betablocker therapy in patients with idiopathic dilated cardiomyopathy (33) may be partly related to increased subendocardial flow
resulting from an increase in diastolic time (decreased heart
rate) and transmural redistribution of blood from the subepicardium to the subendocardium (40),
In the last ten years important progress has been made in the
development of pharmaceutical agents for the management of
patients with chronic heart failure. Research has been directed
toward improving abnormal hemodynamics in these patients.
Although symptomatic improvement may result from the augmentation of cardiac output when inotropic and vasodilating
agents are employed, survival may not be altered (31). Survival
is determined by the amount of myocardial damage and its progression, which may not be affected by such agents (41). To have
a favorable impact on duration as well as quality of life, future
research will need to focus on not only improving cardiac hemodynamics but also preventing further myocardial cell loss or
dysfunction, especially in the early stages of heart failure.

References
1. Braunwald E. Pathophysiology of heart failure. In: Braunwald E, ed. Heart
disease: A textbook of cardiovascular medicine. Philadelphia: W.B, Saunders
Co., 1980:453-71.
2. Eichna LS. Circulatory congestion and heart failure. Circulation
1960:22:864-72.
3. Ribner HS, Breshahan D, Hsieh A, et al. Acute hemodynamic responses to vasodilator therapy in congestive heart failure. Prog Cardiovasc Dis
1982;25:1-42.
4. Tilton GD, Bush L, Wathen M, Buja LM, Willerson JT. What's wrong
with the failing heart? Tex Med 1983:79:35-8.
5. Brian GF. Southwestem Internal Medicine Conference. Chronic congestive heart failure: The nature of the problem and its management in 1984. Am
JMed Sci 1984:288:178-92.
6. Grossman W. Cardiac hypertrophy: Useful adaptation or pathologic process? Am J Med 1980:69:576-84.
7. Graham TP Jr, Ross J Jr, Covell JW. Myocardial oxygen consumption in
acute experimental cardiac depression. Circ Res 1967:21:123-32.
8. Henry PD, Eckberg D, Gault JH, Ross J Jr Depressed inotropic state and
reduced myocardial oxygen consumption in the human heart. Am J Cardiol
1973:31:300-6.
9. Sordal LA. Some biochemical lesions in myocardial disease. Tex Rep Biol
Med 1979:38:121-8.
10. Pool PE, Spann JF Jr, Buccino RA, Sonnenblick EJ, Braunwald E. Myocardial high energy phosphate stores in cardiac hypertrophy and heart failure.
Circ Res 1967:21:365,
11. Alpert NR, Gordon MS. Myofibrillar adenosine triphosphate activity in
congestive failure. Am J Physiol 1962:202:942.
12. Fleckenstein A. Calcium antagonism in heart and smooth muscle. New
York: John Wiley & Sons, 1983.
13. Chidsey CA. Calcium metabolism in the normal and failing heart. In:
Braunwald E, ed. The myocardium: Failure and infarction. New York: HP Publishing Co., 1975:45.
14. Frank O. On the dynamics of cardiac muscle. Am Heart J 1959:58:282,
467.
15. Wiggers CJ, Feil H. The cardio-dynamics of mitral insufficiency. Heart
1922;9:149-83.
16. Rodbard S, Williams F. The dynamics of mitral insufficiency. Am Heart J
1954:48:521-39.

Henry Ford Hosp Med J—Vol 34, No 3, 1986

17. Yoran C, Yellin EL, Becker RM, Gabbay S, Frater RWM, Sonnenblick
EH. Dynamic aspects of acute mitral regurgitation: Effects of ventricular volume, pressure and contractility on the effective regurgitant area. Circulation
1979:60:170-6.
18. Unverferth DV. Magorien RD, Lewis RP, Leier CV. The role of subendocardial ischemia in perpetuating myocardial failure in patients with nonischemic congestive cardiomyopathy. Am Heart J 1983:105:176-9.
19. Bems AS, Schtier RV. The kidney in heart failure. In: Suki WN. Eknoyan
G, eds. The kidney in systemic disease. New York: John Wiley & Sons.
1981:569-93.
20. Zucker IH, Earle AM, Gilmore JP. The mechanism of adaptation of left
atrial stretch receptors in dogs with chronic congestive heart failure. J Clin Invest 1977;60:323-31,
21. Greenberg TT, Richmond WH, Stocking RA, Gupta PD, Meehan JP,
Henry JP. Impaired atrial receptor responses in dogs with heart failure due to
tricuspid insufficiency and pulmonary artery steno.sis. Circ Res 1973:32:424-33.
22. RieggerGAJ, Liebau G, Kocksiek K. Antidiuretic hormone in congestive
heart failure. Am J Med I982;72:49.
23. Gaffney TE, Braunwald E. Importance of the adrenergic nervous system
in the support of circulatory function in patients with congestive heart failure.
Am JMed 1963;34:320-32.
24. Krayenbuehl HPH, Hess OM, Schneider J, Tumer M. Physiologic or
pathologic hypertrophy. Eur Heart J I983;(suppl A):29-39.
25. Unverferth DV. Etiologic factors, pathogenesis, and prognosis of dilated
cardiomyopathy. J Lab Clin Med 1985;106:349-59.
26. Goldstein S. Beta-adrenergic blocking agents in congestive heart failure.
Henry Ford Hosp Med J 1986;34:184-7.
27. Chidsey CA, Braunwald E, Morrow AG. Catecholamine excretion and
cardiac stores of norepinephrine in congestive heart failure. Am J Med
1965:39:442-51.
28. Chidsey CA, Kaiser GA, Sonnenblick EH, et al. Cardiac norepinephrine
stores in experimental heart failure in the dog. J Clin Invest 1964;43:2386-93.
29. Bristow MR. The adrenergic nervous system in heart failure. N Engl J
Med 1984;311:850-1.
30. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine
sensitivity and P-adrenergic-receptor density in failing human hearts. N Engl J
Med 1982:307:205-11.
31. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide
to prognosis in patients with chronic congestive heart failure. N Engl J Med
1984:311:819-23.
32. Thomas J, Marks BH. Plasma norepinephrine in congestive heart failure.
Am J Cardiol 1978:41:233-43.
33. Alderman J, Grossman W. Are [J-adrenergic-blocking drugs useful in the
treatment of dilated cardiomyopathy? Circulation 1985;71:854-7.
34. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after
acute myocardial infarction in patients with congestive heart failure. Circulation
1986:73:503-10.
35. Sonnenblick EH, Factor S, Strobeck JE, et al. The pathophysiology of
heart failure: The primary role of microvascular hyperactivity and spasm in the
development of congestive cardiomyopathy. In: Braunwald E, Mock MB, Watson J, eds. Congestive heart failure: Current research and clinical applications.
New York: Gnine and Stratton, 1982:87.
36. Factor SM, Mina.se T, Cho S, Dominitz R. Sonnenblick EH. Microvascular spasm in the cardiomyopathic Syrian hamster; A preventable cause of
focal myocardial necrosis. Circulation 1982;66:342-54.
37. Dunn RF, Uren RF, Sadick N, et al. Comparison of thallium-201 scanning
in idiopathic dilated cardiomyopathy and severe coronary artery disease. Circulation 1982:66:804-10.
38. Weiss MB, Ellis K, Sciacca RR, Johnson LL, Schmidt DH, Cannon PJ.
Myocardial blood flow in congestive and hypertrophic cardiomyopathy: Relationship to peak wall stress and mean velocity of circumferential fiber shortening. Circulation 1976;54:484-94.
39. Hoffman JIE. Determinants and prediction of transmural myocardial perfusion. Circulation 1978;58:381-91.
40. Herzog CA, Aeppli DP, Bache RJ. Effect of beta-adrenergic blockade
with timolol in myocardial blood flow during exercise after myocardial infarction in dogs. J Am Coll Cardiol 1984;4:1174-83.
41. LeJemtel TH, Sonnenblick EH. Should the failing heart be stimulated? N
Engl JMed 1984;310:1384-5.

Pathophysiology of Heart Failure—Gheorghiade & Lakier

155

